OneSource Specialty Pharma Q1 Standalone Net Profit Rises to 512m Rupees

Market snapshot: OneSource Specialty Pharma Limited delivered a robust financial performance for the first quarter of fiscal year 2026-2027 (Q1 FY27). The company's standalone net profit surged significantly, driven by strong operational execution and a major ramp-up in revenue. On a consolidated basis, the contract development and manufacturing organization (CDMO) successfully turned profitable, supported by the commercial launch of semaglutide products.

Data Snapshot

• Standalone net profit surged ≈106.45% YoY (derived: ₹51.23 cr vs ₹24.82 cr).
• Standalone revenue from operations grew ≈39.52% YoY (derived: ₹446.47 cr vs ₹320.01 cr).
• Standalone EBITDA increased ≈37.84% YoY (derived: ₹110 cr vs ₹79.8 cr).
• Standalone EBITDA margin expanded by ≈65 bps YoY (derived: 25.53% vs 24.88%).
• Consolidated net profit turned profitable at ₹25 cr vs a loss of ₹19 L YoY (derived: ₹25 cr vs -₹19 L).

What's Changed

• OneSource Specialty Pharma has transitioned from a pre-approval phase to a strong commercial revenue phase, backed by the successful launch of its generic semaglutide pens in Canada and India.
• The company's standalone net profit has doubled, expanding operating margins despite rising consumable costs.

Key Takeaways

• Standalone net profit doubled to ₹51.23 crore, showcasing strong operating leverage and high-margin product mix.
• Revenue surged ≈39.52% YoY to ₹446.47 crore, driven by semaglutide rollouts and new Master Service Agreements (MSAs).
• The consolidated group turned profitable with a net profit of ₹25 crore, though subsidiary performance dragged consolidated earnings down by ₹26.23 crore.
• Capacity expansion remains on track, with the second cartridge line expected to commence commercial operations in Q2 FY27.

SAHI Perspective

OneSource is benefiting heavily from its multi-modality CDMO model, especially with the global semaglutide (GLP-1) opportunity taking off. The huge gap between its standalone profit of ₹51.23 crore and consolidated profit of ₹25 crore reflects ongoing losses in step-down subsidiaries like Biolexis and high finance costs. While operational execution is flawless, the legacy litigation with Prestige Biopharma over the Sputnik vaccine poses a significant, albeit contingent, risk to the group's balance sheet.

Market Implications

The robust operational print is likely to support the stock price near-term, especially given the rapid commercialization of complex injectables and peptides. However, investors will closely watch the progression of subsidiary performance to see if the consolidated drag eases in coming quarters.

Trading Signals

Market Bias: Bullish

The company's operational turnaround is highly positive, marked by a standalone PAT surge of ≈106.45% YoY (derived: ₹51.23 cr vs ₹24.82 cr). Solid traction in the GLP-1 segment provides strong near-term visibility.

Overweight: Pharmaceuticals, CDMO

Trigger Factors:

• Commercialization of the second cartridge line in Q2 FY27
• Resolution of the USD 136.32 million Prestige Biopharma legal claim
• Consolidated margin stabilization of subsidiaries

Time Horizon: Medium-term (3-12 months)

Industry Context

The global Contract Development and Manufacturing Organization (CDMO) sector is witnessing a massive surge in demand for complex drug-device combinations, sterile injectables, and peptides (such as GLP-1 agonists). OneSource Specialty Pharma is strategically positioned in this niche, enabling global commercialization for partners across regulated markets like Canada, India, and the US.

Key Risks to Watch

• Ongoing USD 136.32 million Sputnik vaccine legal claim from manufacturing partner Prestige Biopharma, currently pending before the Singapore International Arbitration Centre (SIAC).
• Persistent profit drag from subsidiaries, which reduced consolidated PAT to ₹25 crore compared to standalone PAT of ₹51.23 crore.
• Surging finance costs, which rose 36.9% QoQ to ₹30.81 crore due to capacity expansion debt.
• Potential risk to stock stability as the share price remains highly volatile.

Recent Developments

On May 13, 2026, OneSource announced it decided not to pursue the proposed scheme of arrangement to acquire SteriScience's facilities in Poland and Baroda in its current form, intending to revisit it after the successful delivery of FY28 guidance. In July 2026, Senior Management Personnel Ravi Kumar, Global Head of Injectables and Corporate Strategy, resigned from the company.

Closing Insight

While the standalone performance reflects OneSource's massive operational potential, the ultimate investment thesis relies on the management's ability to clean up subsidiary losses and navigate the SIAC legal overhang successfully.

High Performance Trading with SAHI.